Company profile: Cequent Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of TransKingdom RNA interference (tkRNAi) therapeutics using non-pathogenic bacteria to deliver RNAi into cells to silence disease-causing genes, with pre-clinical drug candidates for colon cancer prevention and inflammatory bowel disease, targeting a wide range of human diseases from inflammatory conditions to cancer.
Products and services
- Colon-cancer prevention drug candidates: Pre-clinical candidates engineered using tkRNAi to deliver RNAi via non-pathogenic bacteria, aiming to silence specific gene targets and prevent colon cancer
- Inflammatory bowel disease drug candidates: Pre-clinical candidates developed with tkRNAi to deliver RNAi directly into cells using non-pathogenic bacteria, silencing specific genes to treat inflammatory bowel disease
- TransKingdom RNA interference (tkRNAi): Proprietary platform leveraging non-pathogenic bacteria to produce and deliver RNAi directly into cells, aiming to silence specific disease-causing genes across inflammatory and cancer indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cequent Pharmaceuticals
Endacea
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting the A1 adenosine receptor, including L-97-1, an intravenous A1 adenosine receptor antagonist for sepsis and acute renal failure, and a mutant plasmid cDNA for cancer administered as an intratumor injection. Both programs are in the preclinical stage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endacea company profile →
Salix Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceuticals focused on preventing and treating gastrointestinal disorders, licensing, developing, and marketing therapies including XIFAXAN for IBS-D and reducing overt hepatic encephalopathy recurrence; RELISTOR for opioid-induced constipation; TRULANCE for chronic idiopathic constipation and IBS-C; UCERIS for ulcerative colitis; MOVIPREP and PLENVU for colonoscopy bowel preparation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Salix Pharmaceuticals company profile →
Genkyotex
HQ: Switzerland
Website
- Description: Provider of innovative drugs and platform technology that block NOX enzymes producing oxygen radicals to treat oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy. Offerings include setanaxib and a NOX inhibitor platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genkyotex company profile →
Exzell Pharma
HQ: Canada
Website
- Description: Provider of medicines, healthcare and biopharma-based products, including EsopH OTC therapy for GERD that relieves heartburn and can be used with PPI prescriptions; Swiss Natural vitamins, supplements and minerals from natural sources; Salinex nasal spray to hydrate and cleanse; PediaVit vitamins and iron for infants and children; Koena multi-strain probiotics; and Ozonol ointment for scrapes, minor burns, and skin irritations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exzell Pharma company profile →
Merus Labs
HQ: Canada
Website
- Description: Provider of pharmaceutical products across broad therapeutic classes, leveraging an opportunistic product acquisition strategy to source acquisition candidates and access targets not available to other players.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Merus Labs company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cequent Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cequent Pharmaceuticals
2.2 - Growth funds investing in similar companies to Cequent Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cequent Pharmaceuticals
4.2 - Public trading comparable groups for Cequent Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →